

May 14, 2025

To,

<b>BSE Limited</b> Phiroze Jeejeebhoy Towers Dalal Street Mumbai - 400 001  <b>Scrip Code (BSE): 544009</b>	<b>National Stock Exchange of India Limited</b> “Exchange Plaza” Bandra-Kurla Complex, Bandra (East) Mumbai – 400051  <b>Symbol: BLUEJET</b>
--	---

**Sub: Press Release – Blue Jet Healthcare for the Audited Financial Results for the quarter and financial year ended March 31, 2025**

Dear Sir / Madam,

In compliance with regulation 30 read with Schedule III to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith Press Release issued by Blue Jet Healthcare Limited.

We request you to take the same on your record.

Thanking you,

Yours faithfully,

For **Blue Jet Healthcare Limited**

**Ms. Sweta Poddar**  
**Company Secretary & Compliance Officer**  
**(M. No.: F12287)**

Unit I

3/2, Milestone, Kalyan Murbad Road, Village Varap, P.O. Box No. 5, Shahad-421 103, **Tel.:** 91 251 2280283 **Fax :** +91 251 2280567

Unit II

Plot No. B-12, C-4, E-2, MIDC, Industrial Area, Chemical Zone, Ambarnath (W) 421501. **Tel. :** +91 8956363877/8956363878

Unit III

K-4/1, Additional MIDC Road, Mahad Industrial Area, Mahad- 402309, **Tel.:** + 91 22 2207 5307 / 6192 / 1691 **Fax :** +91 22 2207 0294

## Blue Jet Healthcare Announces Q4 & FY25 Results

**Highest Q4 Revenue at Rs. 3,404 mn; a jump of 85.1% YoY**

**EBITDA Margins Climb to 41%; up by 1,190bps YoY**

**Mumbai, May 14, 2025: Blue Jet Healthcare Limited (BLUEJET)** (BSE: 544009, NSE: BLUEJET) reported financial results for the quarter and year ended March 31, 2025, on 14<sup>th</sup> May 2025.

### Financial Results – Q4 & FY25

Particulars (Rs. Mn)	Q4FY25	Q3FY25	QoQ	Q4FY24	YoY	FY25	FY24	YoY
Revenue from Operations	3,404	3,184	6.9%	1,839	85.1%	10,300	7,116	44.7%
EBITDA	1,400	1,240	12.9%	531	163.7%	3,777	2,292	64.8%
EBITDA Margin	41.1%	39.0%	211 bps	28.8%	1,226 bps	36.7%	32.2%	446 bps
Exceptional items (*)	0	0		0		0	97	
PAT	1,101	990	11.2%	396	177.7%	3,052	1,638	86.4%
PAT Margin	32.3%	31.1%	125 bps	21.6%	1,078 bps	29.6%	23.0%	662 bps

(\*) The loss of damaged assets and compensation to employees aggregating has been accounted as an exceptional item for the quarter due to Fire incident at one of the facility

**Commenting on results, Mr. Shiven Arora, Managing Director, Blue Jet Healthcare Limited,** said: “Blue Jet has performed exceptionally well in the Q4 and FY25 as a whole. We take pride in informing that the company clocked a revenue of Rs. 10,300 Mn with 44.7% growth Yoy with highest ever EBITDA achieved of Rs. 3,777 Mn for the year. For the quarter, the revenue stood at Rs. 3,404 and EBITDA at Rs. 1,400 Mn. The staggering growth followed by strong EBITDA margins showcases our efforts in operational efficiencies and strong business foundation. This growth was mainly led by the Pharmaceutical Intermediate & API Business.

The Board of directors have proposed a dividend of Rs. 1.2 per share for the year subject to the approval of shareholders. I am delighted to share that the Gadolinium based Intermediate products have been commercialised and the company has started dispatching them in this quarter. We have also been allotted a plot of 30,366 sq. mts. at Dahej III, Industrial Estate Gujarat Area, GIDC for a consideration of Rs. 11.12 cr. With multiple industry tailwinds and a strong vision, we look forward to a good year ahead amidst the global challenges.”

### Key Results Highlights:

#### **Q4 FY25:**

- ✓ **Revenue from operations** for Q4 FY25 stood at **Rs. 3,404 mn** which grew **6.9% QoQ** compared to **Rs. 3,184 mn** in **Q3 FY25; up 85.1% on YoY** basis compared to **Rs. 1,839 mn** in **Q4 FY24**.
- ✓ **Revenue growth** is mainly driven by higher sales in Pharmaceutical Intermediate in Q4 FY25.
- ✓ **Highest ever EBITDA** for the quarter came at **Rs. 1,400 mn**, which was **up 12.9% QoQ** compared to **Rs. 1,240 mn** in **Q3 FY25; up 163.7% YoY** compared to **Rs. 531 mn** in **Q4 FY24**.

- ✓ **EBITDA margin** for the quarter came at **41.1%** as compared to **39.0%** in **Q3 FY25** up **216 bps QoQ**; **28.9%** in **Q4 FY24**, up **1,226 bps YoY**.
- ✓ **PAT** for the quarter was at **Rs. 1,101 mn**, which **grew 11.2% QoQ** compared to **Rs. 990 mn**; up **177.7% YoY** compared to **Rs. 396 mn** in **Q4 FY24**.
- ✓ **PAT margin** for the quarter came at **32.3%** as compared to **31.0%** in **Q3 FY25**, up **125 bps QoQ**; **21.6%** in **Q4 FY24**, up **1,078 bps**.

**FY25:**

- ✓ **Revenue from operations** for **FY25** stood at **Rs. 10,300 mn** compared to **Rs. 7,116 mn** in **FY24**, up **44.7% YoY**
- ✓ **Revenue growth** is mainly driven by higher sales in Pharmaceutical Intermediate in FY25 and **improved profitability** was mainly due to high sales volume, cost optimization leading to absorption of fixed cost.
- ✓ **EBITDA** for **FY25** came at **Rs. 3,777 mn** up **64.8% YoY** compared to **Rs. 2,292 mn** in **FY24**.
- ✓ **EBITDA margin** for **FY25** was at **36.7%** as compared to **32.2%** in **FY24**, up **446 bps YoY**.
- ✓ **PAT** for **FY25** stands at **Rs. 3,052 mn** up **86.4% YoY** compared to **Rs. 1,638 mn** in **FY24**.
- ✓ **PAT margin** for **FY25** was at **29.6%** as compared to **23.0%** in **FY24**, up **662 bps YoY**. **Cash & Cash equivalent and Treasury Investments** stands at **Rs. 2,848 Mn** as on 31<sup>st</sup> March 2025 as compared to **Rs. 3,352 Mn** as on 31<sup>st</sup> March 2024.

**Other Highlights:**

- ✓ Fund Raising approval in the form of QIP, Preferential Issue, Private Placement and / or any other method approved by board for Rs. 15,000 Mn subject to approval from the shareholders.
- ✓ Gadolinium based Contrast Media Intermediate products have been commercialised and the company has started dispatching them in Q4 FY25
- ✓ Final dividend of Rs. 1.2 per share of face value of Rs. 2 each for the year ended March 31, 2025, which is subject to the approval of shareholders at the ensued Annual General meeting of the Company.
- ✓ 30,366.32 sq. mts of plot allotted to Blue Jet Healthcare located at Dahej III, Industrial Estate Gujarat Area, GIDC for a consideration of Rs. 11.12 cr.
- ✓ Demand notice has been received under Section 156 of the Income Tax Act, 1961 amounting to Rs. 1,933.86 million (including interest amounting to Rs. 646.44 million) for the Assessment Years 2020-21 to 2023-24. During the earlier years, the company had provided for the tax amount of Rs. 1,287.42 million in the books of accounts. The matter is currently under appeal before higher authorities. Based on

legal advice, the Company believes it has a strong case both on jurisdictional grounds and on merits and accordingly no further provision is made for interest liability.

**ABOUT BLUE JET HEALTHCARE LIMITED:**

Blue Jet Healthcare Ltd a specialty pharmaceutical and healthcare ingredient and intermediate company, operating under a contract development and manufacturing organization (“CDMO”) business model. The company has specialized chemistry capabilities in contrast media intermediates and high-intensity sweeteners. They have built a long-term customer base with innovator and multi-national generic pharmaceutical companies, supported by multi-year contracts. They supply a critical starting intermediate and several advanced intermediates to three of the largest contrast media manufacturers in the world, including GE Healthcare, Guerbet, and Bracco. They also supply high-intensity sweeteners to several multi-national companies, including Colgate Palmolive (India) Limited and Unilever.

**CAUTIONARY STATEMENT:**

*This press release contains certain forward-looking statements. Any forward-looking statement applies only on the date of this press release. By their nature, forward-looking statements are subject to a number of known and unknown risks and uncertainties that may or may not occur in the future and as a result of which the actual results and performance may differ substantially from the expected future results or performance expressed or implied in the forward-looking statements. No warranties or representations are made as to the accuracy, achievement, or reasonableness of such statements, estimates or projections, and BLUEJET has no obligation to update any such information or to correct any inaccuracies herein or omission here from which may become apparent.*

**For details, please contact:**

<b>Investor Relations at Blue Jet Healthcare Limited</b> Sanjay Sinha, Deputy Chief Financial Officer <a href="mailto:sanjay.sinha@bluejethealthcare.com">sanjay.sinha@bluejethealthcare.com</a>  <b>Ernst &amp; Young</b> Kunal Bhoite <a href="mailto:kunal.bhoite@in.ey.com">kunal.bhoite@in.ey.com</a>  Advait Bhadekar <a href="mailto:Advait.bhadekar@in.ey.com">Advait.bhadekar@in.ey.com</a>	<b>Registered Office</b> 701,702, 7th Floor, Bhumi Raj Costarica, Sector 18, Sanpada, Navi Mumbai Thane 400705, Maharashtra, India CIN: U99999MH1968PLC014154 ISIN: INE0KBH01020 NSE Code: BLUEJET BSE CODE: 544009 Website: <a href="http://www.bluejethealthcare.com">www.bluejethealthcare.com</a>
---	---